Literature DB >> 16490727

Guidelines for the use of antidepressants in painful rheumatic conditions.

Serge Perrot1, Emmanuel Maheu, Rose-Marie Javier, Alain Eschalier, Anne Coutaux, Manuela LeBars, Philippe Bertin, Bernard Bannwarth, Richard Trèves.   

Abstract

OBJECTIVES: Antidepressants are widely used to treat painful chronic rheumatic conditions but, contrary to neuropathic conditions, little is known about their true analgesic properties and value in these situations. Our group, which focuses on pain in rheumatology, aimed to develop recommendations for the use of antidepressants in rheumatology, based on evidence-based review of published data and expert opinion.
METHOD: We identified relevant drugs and conditions and searched Medline, Embase and Pascal (1966-2003) for relevant publications in a number of European languages. We scored each study for quality, and used an expert consensus approach to formulate recommendations.
RESULTS: We identified 77 studies and 12 meta-analyses and literature review on the use of antidepressant to treat painful rheumatological conditions. Forty-nine of these clinical studies were considered valid and were used to develop the recommendations. When evidence was lacking we based recommendations on our clinical experience.
CONCLUSIONS: These recommendations for the treatment of painful rheumatological conditions with antidepressants were developed using evidence-based and expert consensus approaches and are the first of their kind in this field. Our review of the literature highlights the need for further, well-designed clinical studies of the use of antidepressants to treat painful rheumatological conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16490727     DOI: 10.1016/j.ejpain.2005.03.004

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  7 in total

1.  Antidepressant Fluoxetine Does Not Appear to Interfere With Key Translational Parameters in the Rat Adjuvant-induced Arthritis Model.

Authors:  Dasa Seveljevic-Jaran; Otto Kalliokoski; Klas S P Abelson; Jann Hau
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

2.  To what degree do shoulder outcome instruments reflect patients' psychologic distress?

Authors:  Young Hak Roh; Jung Ho Noh; Joo Han Oh; Goo Hyun Baek; Hyun Sik Gong
Journal:  Clin Orthop Relat Res       Date:  2012-08-21       Impact factor: 4.176

Review 3.  Antidepressants for the treatment of chronic pain.

Authors:  Bénédicte Verdu; Isabelle Decosterd; Thierry Buclin; Friedrich Stiefel; Alexandre Berney
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  Disruption of 5-HT2A receptor-PDZ protein interactions alleviates mechanical hypersensitivity in carrageenan-induced inflammation in rats.

Authors:  Anne-Sophie Wattiez; Xavier Pichon; Amandine Dupuis; Alejandro Hernández; Anne-Marie Privat; Youssef Aissouni; Maryse Chalus; Teresa Pelissier; Alain Eschalier; Philippe Marin; Christine Courteix
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

5.  A methodological quality assessment of systematic reviews and meta-analyses of antidepressants effect on low back pain using updated AMSTAR.

Authors:  Mohammad Hossein Panahi; Mostafa Mohseni; Razieh Bidhendi Yarandi; Fahimeh Ramezani Tehrani
Journal:  BMC Med Res Methodol       Date:  2020-01-23       Impact factor: 4.615

6.  The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis - a pooled analysis of five randomised controlled trials.

Authors:  Arkady T Manning-Bennett; Ashley M Hopkins; Michael J Sorich; Susanna M Proudman; David J R Foster; Ahmad Y Abuhelwa; Michael D Wiese
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-07-22       Impact factor: 3.625

7.  General practitioner management of shoulder pain in comparison with rheumatologist expectation of care and best evidence: an Australian national survey.

Authors:  Rachelle Buchbinder; Margaret P Staples; E Michael Shanahan; Juliana F Roos
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.